How Device Firms Can Play the Pricing Game to Improve Franchise Value
Price erosion--and its significant impact on profitability--has been a way of life for most medical device companies for years. But changes in the markeplace, particularly in GPO contracting strategies, may open the door to a re-thinking of the inevitability of price discounts. For many medical device and supply companies, the potential impact from raising the game on pricing performace is significant and available now. It can add 15-30% or more in franchise value and be a source of sustained competitive advantage.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.